Dr Reddy's Laboratories to Split 1:5: Potential for Growth Ahead of Q2 Results

Dr Reddy's Laboratories, a large-cap pharma stock, is preparing for its second stock split, this time in the ratio of 1:5, just before the Diwali festival. This stock split marks a significant opportunity for new and existing investors as the pharma giant aims to make its shares more affordable. Notably, this is the company's first stock split in 23 years. The stock is currently positioned for potential growth ahead of the release of its Q2 results, with Phillip Capital setting a bullish target price of Rs 7,300, which implies a potential 11% rise in the stock's value.

Dr Reddy's Laboratories Share Price Overview

The latest share price of Dr Reddy's Laboratories on BSE stands at Rs 6,601.25 per share, with the company holding a market capitalization of Rs 1,10,154.49 crore. The stock's 52-week high is Rs 7,101 apiece, while the 52-week low is Rs 5,212.10 apiece.

Key financial metrics for Dr Reddy's include:

• Price-to-equity (P/E) ratio: 26.73x
• Return on equity (ROE): 17%
• Year-to-date (YTD) growth: Over 13.5% on BSE
• 1-year upside: About 21%
• 5-year return: 149.39%, marking the stock as a multi-bagger

Dr Reddy's Laboratories Stock Split Details

Dr Reddy's will undergo a 1:5 stock split, making shares more affordable to retail investors. For every one equity share of Rs 5/- each, fully paid-up, shareholders will receive five equity shares of Re. 1/- each, fully paid-up.

• Record Date: Monday, October 28, 2024

To be eligible for this stock split, investors must hold shares by the end of the record date. This is the company's second stock split, with the first occurring in October 2001, when the face value was reduced from Rs 10 to Rs 5 in a 1:2 ratio.

Future Growth Potential

Brokerage Phillip Capital is optimistic about Dr Reddy's Laboratories and has set a target price of Rs 7,300, forecasting an 11% rise from current levels. The company's positive performance in 2024, along with its financial health, makes it a strong contender for future growth. Investors might find this a compelling opportunity to buy ahead of the Q2 earnings results and the upcoming stock split.

Final Thoughts

Dr Reddy's Laboratories is preparing for a major stock event with its 1:5 stock split scheduled for late October. The stock has delivered strong returns, making it an attractive option for both short-term gains and long-term investments. Investors looking to capitalize on the stock split and Q2 results should consider holding shares by the record date to benefit from this opportunity.

---

Disclaimer: This post is for informational purposes only. Always conduct your own research or consult with a financial advisor before making any investment decisions.